In the univariate analysis, there was a clear trend towards an increased risk of infection in the 6 months following rituximab (odds ratio: 1.51, 95% CI [0.90–2.56], p = 0.1).
← all phrases
“a clear trend”
Sighted at
p<0.09
In the literature
Importantly, a clear trend towards very low MICA values was observed in these patients (Table 4 , P value = 0.10).
Treatment of STC-1 cells with PKI-14-22 (100 nM), a selective PKA inhibitor, led to a clear trend ( P = 0.104) toward a reduction in glucose-stimulated GIP release ( Fig. 10B ).
Although there was a clear trend toward an increased incidence of EDIF with lowering of serum vitamin D levels, no statistically significant difference (P=0.105) was found among these three groups.
There is a clear trend suggesting that diabetes exacerbates cognitive dysfunction in schizophrenia (global cognition: SMD=−0.26; P = 0.1087; 95% CI, −0.59 to 0.08), particularly in domains such as reasoning (SMD=−0.40; P = 0.0109, 95% CI −0.58 to -0.22) and processing speed (SMD=−0.43; P = 0.0005, 95% CI −0.52 to −0.35).
Positive trends were present throughout the analysis, including a clear trend of improvement in parent enablement for the intervention families ( P =.11).
However, there was a clear trend in the risk of ATE in patients with pre-MF (18.2% vs. 7.8%, p = 0.11).
Additionally, there was a clear trend ( p = 0.11) towards lower QoL in patients who have been previously treated with topical agents containing corticosteroids ( n = 32; 9.5 ±5.9 points vs. n = 44; 6.7 ±4.2 points).
A clear trend was also demonstrated by mIF imaging for increased intratumoral CD3 + CD8 + PD1 + T cell infiltrates in the T cell-inflamed versus non-T cell-inflamed (p=0.11) or intermediate (p=0.20) UPMC samples ( figure 1D ), further validating the immunophenotypic groups used for downstream analysis.
Concerning the time interval between curative treatment of the primary tumour and the occurrence of metachronous CRLM, there was a clear trend for an impaired DFS of patients diagnosed with EM-CRLM (DFS: 14 vs. 28 months; p = 0.11).
TNM stage did not reach any statistical significance with USP9X expression; however, it displayed a clear trend (P = 0.112).
In addition, there was a clear trend towards a decrease in the length of hospital stay: 19.5 (8.0–22.3) vs. 10.0 (6.8–15.3) days, P = 0.112 ( Figure 1 D ).
This effect was attenuated by the presence of minor alleles rs35643203 and rs12201140, which showed a clear trend towards low VIP level association (p = 0.118 and p = 0.049, respectively).
HCC patients with baseline miR-107 expression levels above a calculated ideal prognostic cut-off value (9.82) showed a clear trend towards an impaired overall survival (p = 0.119).
Although no longer significant, there was still a clear trend with a 1.90 higher odds of pCR if patients had a low stromal content (OR 1.90, 95% CI 0.85‐4.25, P = .119).
However, when the expression level measured 100 days after surgery was analyzed, a clear trend towards reduced over survival time in the high-expression patients was stated (low expression n = 10, high expression n = 11; p = 0.1197; log-rank test; Fig. 3 C).
When considering patients with COVID-19 for the analysis (matched for time since symptoms onset: median, 3 days in both groups), a clear trend ( P = 0.12) towards higher viral RNA loads was observed in non-vaccinated individuals (8.1 log 10 copies/ml; range, 3.3–11.6) compared with vaccinated participants (median, 7.4 log 10 copies/ml; range, 3.3–11.2).
Although, we noted a clear trend (P=0.12) between the groups, we prefer to not add these data into the current manuscript.
Although the SR in worsening BCVA was not statistically significant, there was a clear trend towards a better outcome in the group receiving 7 or more injections (88.9% versus 69.7%, P = 0.12).
While both groups demonstrated a clear trend towards greater exacerbation rates (1.41 [95% CI: 0.91, 2.19], p = 0.124 and 1.35 [95% CI: 0.99, 1.84], p = 0.054, respectively) in comparison with the reference group, this did not reach statistical significance (Fig. 3 ).
Although showing a clear trend, the difference did not reach statistical significance ( P =.13).
While there was a clear trend towards increased clearance time with increasing rHuEpo dose the effect did not reach statistical significance (Mann-Whitney U test, P=0.13).
2 A , there is a clear trend toward a difference in the composite primary end point (ulcers or nonulcerative lesions) across the full follow-up period ( P = 0.13).
However, the multivariate analysis in our study showed a clear trend for younger age as a predictor of a moderate–severe MIDAS score (OR 1.09, p = 0.13).
There was a clear trend ( p = 0.13) that the distribution of females and males was different in the three different patient subgroups.